Why VEON (VEON) Is Up 5.2% After Raising 2026 Revenue Guidance Despite Weaker Q2 Earnings
VEON Ltd. Sponsored ADR VEON | 0.00 |
- In July 2026, VEON Ltd. reported its second-quarter 2026 results, with sales rising to US$1,271 million from US$1,087 million a year earlier, while net income fell to US$122 million from US$595 million and basic earnings per share from continuing operations dropped to US$1.75 from US$8.5.
- At the same time, VEON raised its full-year 2026 revenue growth guidance to a 15% to 18% year-over-year increase, up from its prior 11% to 14% range, signaling greater confidence in its top-line outlook even as profitability softened compared with the previous year.
- We will now examine how VEON’s higher 2026 revenue growth guidance reshapes its existing investment narrative and future earnings assumptions.
Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
VEON Investment Narrative Recap
To own VEON today, you need to believe its push into digital services and emerging-market connectivity can translate stronger revenue growth into durable earnings, despite volatile markets and high leverage. The latest results highlight this tension: revenue rose, guidance improved, but net income and margins weakened. That combination keeps the main near term catalyst intact, namely faster top line growth from digital and multiplay users, while sharpening the key risk that earnings and cash flow may not keep pace.
Among recent developments, VEON’s expanded partnership with Mastercard across Ukraine, Kazakhstan, Pakistan and Uzbekistan looks especially relevant. It sits right at the intersection of the upgraded 2026 revenue guidance and the core growth thesis around fintech and digital ecosystems, but it also raises the stakes on execution quality, capital intensity and regulatory risk in markets already exposed to currency and political uncertainty.
Yet against this stronger revenue story, investors should still pay close attention to how VEON’s high debt load and weaker margins could affect...
VEON's narrative projects $5.7 billion revenue and $645.7 million earnings by 2029. This requires 7.6% yearly revenue growth and a $113.7 million earnings increase from $532.0 million today.
Uncover how VEON's forecasts yield a $83.44 fair value, a 49% upside to its current price.
Exploring Other Perspectives
Before this guidance upgrade, the most optimistic analysts were assuming VEON could reach about US$5.1 billion in revenue and US$843.2 million in earnings by 2028, which is far more bullish than the baseline view and sits uncomfortably alongside the recent margin squeeze and the added risk that digital expansion may require heavier up front investment than many of us previously assumed.
Explore 5 other fair value estimates on VEON - why the stock might be worth 9% less than the current price!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your VEON research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
- Our free VEON research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate VEON's overall financial health at a glance.
No Opportunity In VEON?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
- Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
- AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
